Status:
COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Single ascending dose of HM15211 in healthy obese subjects.
Detailed Description
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Eligibility Criteria
Inclusion
- Female subjects must be non-pregnant and non-lactating
Exclusion
- Participation in an investigational study within 30 days prior to dosing
Key Trial Info
Start Date :
April 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 14 2018
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT03374241
Start Date
April 4 2018
End Date
September 14 2018
Last Update
February 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Investigative Site
Chula Vista, California, United States, 91911